Bionxt launched the final animal study needed to prepare for human testing of BNT23001, its under-the-tongue version of ...

The large-mass animal crossover bioequivalence study will commence in the next two to three weeks and will be carried out ...

Tonmya demonstrated significant reduction in fibromyalgia pain compared with placebo in the Phase 3 RESILIENT studyTreatment ...

BioNxt Solutions Inc. (CSE:BNXT) (OTCQB:BNXTF) (FSE:BXT), a bioscience company developing next-generation drug delivery technologies, has launched a 15-day dosing optimization study for its lead ...

Share on Facebook. Opens in a new tab or window Share on Bluesky. Opens in a new tab or window Share on X. Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window CHICAGO -- A ...

Please provide your email address to receive an email when new articles are posted on . The review included 11 trials and more than 6,000 patients. Improvements included symptoms, sleep, emotions, ...

What if the COVID-19 vaccine could be a simple drop under the tongue instead of a shot in the arm? That's the result researchers from Japan’s Intelligence & Technology Lab Inc. and the Biomedical ...

Sublingual immunotherapy for peanut allergy was safe and effective among children aged 2 to 12 years, making it a promising alternative to oral immunotherapy, according to a study published in The ...

Two new studies highlight the challenges for patients in sticking with allergy shots or sublingual immunotherapy. Both studies add to arguments in favor of having frank discussions before selecting ...

For acute ischemic stroke within 48 hours of onset, the novel sublingual combination of edaravone (Radicava) with dexborneol appeared to dramatically improve functional outcomes in the phase III TASTE ...

Detailed price information for Aspire Biopharma Holdings Inc (ASBP-Q) from The Globe and Mail including charting and trades.